...sue microarrays are derived from Paraffin embedded...ality control procedures to ensure the highest qua... in one block, sectioned at a thickness of 5 micro...e (3-5 mm in diameter) in comparison to core secti...
...standards consist of seven reduced, denatured prot... bovine carbonic anhydrase, rabbit muscle GAPDH, b...min) with pIs ranging from 4.5 to 8.5 and molecula... standards provide calibrated references for the p...
PROTEAN II xi Multi-Cell 2-D Conversion Kit from Bio-Rad
Printer Paper for Model 680 Series Readers, 2 rolls from Bio-Rad
Biology Products:(Date:11/30/2009)..., , AMSTERDAM, November 30 /PRNewswi...ounces today that the first patients have been enr...rial with ATIR(TM). The study is,designed to show ...ter one,year following an allogeneic stem cell tra...onor in blood cancer patients eligible for an allo...
(Date:11/30/2009)..., , CHANGCHUN, China and LOS ANGEL...ongxin Pharmaceuticals, Inc. (OTC Bulletin Board: ...any,), a leading manufacturer, distributor and,ret...day announced it has,completed preparation for dis... , The Chinese government recently formal...
(Date:11/30/2009)..., , NOVATO, Calif., Nov. 30 /PRNewswire-Fi... BMRN ) announced today that the Food and Drug Adm...ion for 3,4-diaminopyridine (3,4-DAP), amifampridi...ert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has...e E.U. Also, in October 2009, the Committee for M...
(Date:11/30/2009)..., , SEATTLE, Nov. 30 /PRNewswire-Fi...and MTA: CTIC) announced today that its new class ...-platinates, demonstrated a stronger anti-tumor po... platinum-based compounds as well as the ability t...es. The results were presented in a paper titled ...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3